{"entity":{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","aka":["Hummingbird Bioscience Pte Ltd"],"tldr":"Hummingbird Bioscience is a Singapore biotech that uses computational biology to pick hard-to-reach antibody epitopes; its HER3 antibody HMBD-001 was developed with Cancer Research UK.","summary":"Hummingbird Bioscience uses its Rational Antibody Discovery platform to design antibodies against epitopes that block receptor function. HMBD-001 binds the dimerisation interface of HER3 and prevents ligand-dependent and ligand-independent signalling; it entered the clinic with Cancer Research UK in advanced solid tumours including NRG1 fusion-positive cancers. Other programmes include the VISTA antibody HMBD-002 and antibody-drug conjugates.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hummingbirdbioscience.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hmbd-001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://www.hummingbirdbioscience.com/","founded":2015,"investors":[],"funding":[]},"route":"/companies/hummingbird-bioscience/","neighbours":{"drug":[{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/"}]}}